Core Viewpoint - Heng Rui Medicine (01276) reported a significant increase in revenue and net profit for the first three quarters of 2025, alongside the approval of a new diabetes treatment, marking a notable innovation in the field [1]. Financial Performance - The company achieved an operating revenue of 23.188 billion yuan, representing a year-on-year increase of 14.85% [1]. - The net profit attributable to shareholders was 5.751 billion yuan, reflecting a year-on-year increase of 24.5% [1]. - Basic earnings per share were reported at 0.89 yuan [1]. Product Development - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its self-developed drug, Henggeli Jing Regaglitin Metformin Sustained-Release Tablets (I) and (II) (Rui Letang®) [1]. - Rui Letang® is noted as the first domestically developed oral triple combination preparation for diabetes treatment in China, indicating a significant breakthrough in diabetes management [1].